baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ocular Therapeutix/ US67576A1007 /

2024-04-29 9:59:57 PM	Chg. +0.05	Volume	Bid-	Ask-	High	Low
4.79USD	+1.05%	64,870 Turnover: 323,436.16	-Bid Size: -	-Ask Size: -	5.16	4.75

GlobeNewswire 04-18 Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

GlobeNewswire 04-16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 04-15 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...

GlobeNewswire 04-09 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...

GlobeNewswire 04-06 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...

GlobeNewswire 03-26 Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract a...

GlobeNewswire 03-11 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire 03-05 Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

GlobeNewswire 02-22 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed...

GlobeNewswire 02-22 Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

GlobeNewswire 02-22 Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

GlobeNewswire 02-15 Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

GlobeNewswire 02-13 Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ ...

GlobeNewswire 02-12 Accelus Strengthens Leadership with New Board Appointments

GlobeNewswire 02-08 Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Promptin...

GlobeNewswire 01-25 Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal C...

GlobeNewswire 2023-12-18 Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underw...

GlobeNewswire 2023-12-14 Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

GlobeNewswire 2023-12-13 Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

GlobeNewswire 2023-11-08 Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

GlobeNewswire 2023-11-07 Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

GlobeNewswire 2023-11-01 Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Piv...

GlobeNewswire 2023-10-24 Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

GlobeNewswire 2023-10-03 Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

GlobeNewswire 2023-09-06 Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Ocular Therapeutix/ US67576A1007 /

If you wish to receive reply to your feedback, please provide your email address.